Application of PRG4 in enhancing the developmental potential of early mammalian embryos in vitro
By adding rhPRG4 protein to the early embryo culture system, the problem of early embryonic developmental arrest was solved, the embryo implantation rate was improved, the interaction between the embryo and the mother was enhanced, and a higher embryo transfer success rate was achieved.
Patent Information
- Application Number
- CN202611069064.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-17
- Publication Date
- 2026-11-17
AI Technical Summary
Early embryonic developmental arrest is a common phenomenon in the in vitro culture of mammalian embryos. Current technology lacks effective intervention strategies, which affects embryo implantation ability and pregnancy outcomes.
Adding recombinant human proteoglycan 4 (rhPRG4) protein to the early embryo culture system can improve the embryo culture microenvironment, promote the interaction between the embryo and the mother, and enhance the embryo implantation ability.
It significantly improved the implantation rate and enhanced the embryo implantation ability after embryo transfer, providing a new technical means to improve the success rate of embryo transfer in primates and other mammals.
Smart Images

Figure CN123107914A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of embryo engineering and assisted reproductive technology, and more specifically, relates to the application of proteoglycan 4 (PRG4) in improving the developmental potential of early mammalian embryos in vitro. Background Technology
[0002] Early embryo in vitro culture is one of the core components of embryo engineering technology. It refers to the technical system of allowing embryos produced through in vitro fertilization or somatic cell nuclear transfer to develop continuously in vitro under suitable temperature and mixed gas conditions. Taking cynomolgus monkeys as an example, the normal in vitro culture embryo development process is as follows: the day of ICSI is defined as day 0 of embryonic development. The fertilized egg completes fertilization 4-6 hours after ICSI, forming two polar bodies and two pronuclei. About 20 hours after ICSI (day 1), the embryo undergoes its first cleavage to form a 2-cell embryo. On the morning of day 2 (about 40 hours), it divides into 4-cells, and in the afternoon (about 48 hours), 6 to 8-cells can be observed. After the embryo reaches a certain number of cells through multiple divisions, it enters the morula stage on day 5 when the intercellular spaces shrink and there are no obvious independent cell morphologies under the microscope. From day 6 to day 7, the shrunken morula expands to form the blastocoel and differentiates into the clearly defined trophoblast (TE) and inner cell mass (ICM), completing the first cell lineage differentiation of the early embryo. The quality of this continuous developmental process determines whether the embryo has a normal implantation ability, which in turn affects the pregnancy outcome.
[0003] However, early embryonic developmental arrest is a common phenomenon in mammalian embryo culture. Statistics show that the blastocyst development rate of bovine oocytes after IVM before transfer to recipient cows is only about 30%. Of all human embryos produced through IVF or ICSI, approximately 10% permanently arrest at the primary cleavage stage, and over 40% of patients experience at least one arrested embryo per cycle. Human embryonic developmental arrest commonly occurs at the four- to eight-cell stage, in mice at the two-cell stage, and in cattle at the eight- to sixteen-cell stage. The blastocyst rate of cynomolgus monkey embryos in vitro averages only around 40%, with a large number of embryos potentially experiencing developmental arrest at the 2-8 cell, 16-cell, and morula stages. Although studies have shown that embryonic developmental arrest is associated with chromosomal abnormalities, DNA damage, oxidative stress, zygotic genome activation (ZGA) failure, and disordered expression of multiple factors, early embryonic development is a highly complex and rapid process of cell proliferation and differentiation, regulated by multiple factors. Its specific mechanisms are not yet fully understood, and effective intervention strategies remain scarce. Summary of the Invention
[0004] Based on the aforementioned deficiencies in the existing technology, the present invention first provides a method for improving the early embryo implantation potential and embryo transfer success rate by utilizing proteoglycan 4 (PRG4).
[0005] Proteoglycan 4 (PRG4), also known as lubricin, is encoded by a gene located on human chromosome 1, 1q31.1, and is highly conserved in various mammals, including humans, chimpanzees, rhesus monkeys, cattle, and rats. The protein encoded by PRG4 is a highly glycosylated mucoid glycoprotein. As an important component of the extracellular matrix, it plays a crucial role in tissue lubrication, cell signaling regulation, and maintaining tissue homeostasis by interacting with cell surface receptors such as CD44.
[0006] Previous studies have shown that recombinant human PRG4 (rhPRG4) possesses multiple biological functions. In tissue repair and regeneration, rhPRG4 can regulate fibrosis, angiogenesis in the damaged area, and macrophage inflammation, and promote the proliferation of mesenchymal progenitor cells and chondrocyte differentiation. Regarding vascular system regulation, rhPRG4 can inhibit the migration of venous smooth muscle cells, adventitia cells, and endothelial cells, and regulate endothelial cell proliferation. In tumorigenesis and development, PRG4, as a downstream regulatory molecule of myxoid liposarcoma-associated fusion oncoproteins TLS-CHOP and EWS-CHOP, may have its aberrant expression affect tumor cell biological behavior. In inflammation regulation, PRG4 participates in synovial macrophage polarization and inflammatory macrophage tissue infiltration; the absence of PRG4 expression can lead to chronic inflammation and fibrosis.
[0007] Furthermore, studies have found that PRG4 can reduce oxidative stress levels in chondrocytes and inhibit apoptosis, suggesting its important role in maintaining cellular homeostasis and regulating the microenvironment. However, the function of PRG4 in early embryonic development and implantation has not yet been systematically reported. This invention is the first to discover that PRG4 participates in the regulation of early embryo implantation and improves embryo implantation ability by improving the embryo culture microenvironment and promoting embryo-maternal interface interactions, providing new theoretical basis and technical solutions for optimizing assisted reproductive embryo culture systems and improving embryo transfer success rates.
[0008] The objective of this invention is achieved through the following technical solution:
[0009] This invention first provides the application of rhPRG4 as a culture medium additive in improving the implantation rate of cynomolgus monkeys after in vitro culture and embryo transfer.
[0010] This invention also provides the application of PRG4 as a target for improving the implantation rate of early cynomolgus monkey embryos in vitro.
[0011] Preferably, in the above applications, PRG4 acts as a positive regulator of improving the implantation rate of early cynomolgus monkey embryos in vitro.
[0012] This invention utilizes blastomere biopsy technology to obtain individual blastomeres cultured in vitro to the 4-cell and 8-cell stages. Bioinformatics analysis was performed on single-tube single-cell RNA sequencing (based on Smart-Seq2 amplification, obtaining full-length transcripts and then using Tn5 transposase for library construction and sequencing) to identify differentially expressed mRNAs between the groups. Specifically, blastomeres from cynomolgus embryos cultured in vitro at the 4-cell and 8-cell stages were mechanically biopsied. A single surviving blastomer was removed, rapidly frozen in 5 μL of lysis buffer, and used for transcriptome sequencing. The remaining embryos were cultured until day 7. Based on the developmental outcome of the remaining embryos, the biopsied blastomeres were divided into a high-potential group (the remaining embryos developed into expanded blastocysts) and a low-potential group (the remaining embryos developed arrested or degenerated). By comparing differentially expressed mRNAs between the two groups, we explored the molecular mechanisms of embryonic developmental arrest at the transcriptomic level and screened key genes that may ensure normal embryonic development.
[0013] Transcriptomic analysis showed that PRG4 mRNA exhibited high transcription levels in multiple blastomeres from the 4-cell high developmental potential group, while expression was undetectable in 4-cell blastomeres from the low developmental potential group. High expression persisted during the 8-cell stage, but PRG4 expression was silenced in the morula and blastocyst stages. Given that PRG4 is a secreted protein, the inventors added recombinant human PRG4 (rhPRG4) protein to the culture medium of fertilized eggs and early embryos.
[0014] To rapidly and efficiently assess the impact of PRG4 on embryo implantation potential, this invention established a xenograft model of cynomolgus monkey embryos transplanted into the uterus of immunodeficient NOD-Scid mice. Results showed that, unlike the typical implantation sinuses formed by mouse embryos, cynomolgus monkey embryo implantation induced diffuse edema in the recipient mouse uterus, with localized tissue protrusions, which this study identified as implantation sinuses. Further tissue sections confirmed the presence of blastocyst structures within these protrusions, validating the feasibility of this model for assessing the implantation potential of primate embryos.
[0015] Results of in vitro culture with rhPRG4 supplementation showed no significant effect on blastocyst formation rate. However, further validation through embryo transfer experiments revealed that early embryo culture with rhPRG4 significantly improved the pregnancy rate in the xenograft model, increasing it from 37.5% (3 / 8) in the control group to 80.0% (4 / 5). This indicates that while PRG4 does not affect the ability of embryos to develop into blastocysts in vitro, it can significantly enhance the implantation ability of blastocysts.
[0016] Therefore, PRG4 can serve as an effective target for improving the implantation rate of early cynomolgus monkey embryos in vitro, by promoting implantation through improving embryo-endometrial interactions or the immune microenvironment.
[0017] In the specific process of early embryo in vitro culture, recombinant human PRG4 protein can be added to the culture medium of fertilized eggs and early embryos.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] This invention reveals for the first time the crucial promoting role of PRG4 in the regulation of early embryo implantation. The study found that PRG4 is specifically highly expressed in high-development-potential 4-cell stage blastomeres, while its expression is absent in low-development-potential 4-cell stage blastomeres. This indicates that PRG4 is closely related to embryonic developmental potential and subsequent implantation ability, and can serve as an important molecular marker for evaluating embryo quality and implantation potential.
[0020] This invention significantly improves the implantation rate of embryos after transplantation by adding recombinant human PRG4 (rhPRG4) protein to the early embryo culture system. This indicates that PRG4 can enhance embryo implantation ability by regulating the embryo culture microenvironment and promoting the interaction between the embryo and the mother, providing a new technical means to improve the success rate of embryo transfer in primates and other mammals.
[0021] This invention establishes a research system for embryo implantation regulation that integrates blastomere biopsy, single-cell transcriptome analysis, candidate gene screening, and functional verification. This system can be used to systematically screen and verify key regulatory factors that affect embryo development potential and implantation ability, providing a theoretical basis and technical support for developing novel assisted reproductive culture additives, optimizing embryo culture systems, and improving the efficiency of assisted reproductive technologies. Attached Figure Description
[0022] Figure 1 A schematic diagram of a single blastomere embryo biopsy and sampling.
[0023] Figure 2 Flowchart for single-tube, single-blastomere / single-embryo transcriptome sequencing;
[0024] Figure 3Heatmap of C4LDP / C4HDP binary expression characteristic genes;
[0025] Figure 4 Analysis of PRG4 expression patterns at different developmental stages in early embryos of cynomolgus monkeys;
[0026] Figure 5 Comparative images of morphological implantation of cynomolgus monkey embryos in the uterus of NOD-Scid mice;
[0027] Figure 6 Histological section (HE staining) of the implantation site of cynomolgus embryos in the uterus of NOD mice;
[0028] Figure 7 Statistical graph showing the effect of adding rhPRG4 protein to culture on blastocyst formation rate;
[0029] Figure 8 A statistical chart showing the pregnancy rate after embryo transfer of cultured blastocysts with added rhPRG4 protein. Detailed Implementation
[0030] To better illustrate the purpose, technical solution, and advantages of this invention, the invention will be further described below with reference to specific drawings and embodiments. Unless otherwise specified, the experimental methods used in the embodiments are conventional methods, and the materials and reagents used are commercially available unless otherwise specified.
[0031] Example 1
[0032] I. Definition of High and Low Developmental Potential Groups in Embryonic Blastomere Biopsy
[0033] In mammalian embryonic development, the embryo begins with a fertilized egg. The fertilized egg undergoes cleavage to produce blastomeres, which are totipotent in early embryos (2-8 cells). Blastocyst biopsy is one of the important sampling methods for clinical preimplantation genetic testing (PGT). Embryos from different cynomolgus monkeys (ensuring samples from at least two individuals at each stage) are randomly selected, and blastomeres are biopsied at the 2-cell, 4-cell, and 8-cell stages. To ensure that the biopsy process does not affect embryonic development and the biological integrity of the retrieved blastomeres, this invention employs a mechanical method: a large "cross-shaped" incision is made in the zona pellucida, and a relatively thick biopsy needle is used to remove one blastomere. Figure 1As shown, blastomeres of cynomolgus embryos cultured in vitro were mechanically biopsied at the 2-cell, 4-cell, and 8-cell stages. While obtaining a single surviving blastomere for transcriptome sequencing, the remaining blastomeres were cultured to the blastocyst stage. Furthermore, in this study, 2-cell embryos were mechanically divided in half, and one surviving hemimorula was extracted from the morula stage on day 5 for transcriptome sequencing. Based on the final developmental outcome on day 7, the sequencing samples from the early blastomeres and hemimorula were divided into two groups: high developmental potential (HDP) and low developmental potential (LDP), corresponding to samples that ultimately formed blastocysts and those that did not, respectively.
[0034] II. Transcriptomics Detection and Result Analysis
[0035] Samples were amplified within one week, and full-length transcripts were obtained using a Smart-Seq2-based single-tube, single-cell / single-embryo RNA sequencing method. Library construction and sequencing were then performed using Tn5 transposase. This amplification method can be used not only for quantitative transcript analysis but also for the interpretation of structural variations and functional information. The specific experimental and information analysis procedures are as follows: Figure 2 As shown.
[0036] This study performed a systematic transcriptome differential analysis on 2-cell, 4-cell, 8-cell, and morula embryos of HDP and LDP. The results are as follows: Figure 3 The results showed that PRG4 was a gene with significant differences between the HDP and LDP groups during the 4-cell stage. Figure 4 As shown, further analysis of the expression pattern of PRG4 throughout the early embryonic developmental stages from MII oocytes to blastocysts revealed that PRG4 was expressed at a low level from MII oocytes to 2-cell embryos; its expression level increased sharply in the high developmental potential group (C4HDP) at the zygote genome activation stage, showing a difference from the completely non-expressing low developmental potential group (C4LDP); it continued to be expressed in the developmental group at the 8-cell embryo stage; and PRG4 expression was silenced when developing to the morula and blastocyst stages.
[0037] III. Establishment of a system for xenotransplantation of cynomolgus monkey embryos into NOD-Scid mice
[0038] To rapidly and efficiently assess the impact of PRG4 on embryo implantation ability, this study established a xenograft model of cynomolgus monkey embryos transplanted into the uterus of immunodeficient NOD-Scid mice.
[0039] The model construction method is as follows:
[0040] 1. Preparations for neutering male rats
[0041] Several weeks in advance, C57 male mice underwent vasectomy via surgery. After recovery, they were raised and fed separately. Once mating was confirmed to be infertile but capable of normal mating, they could be used for breeding 1-2 times per week.
[0042] 2. Preparation of pseudopregnant NOD-scid receptor mice
[0043] Sexually mature female NOD mice were co-occupied with vasectomized male mice overnight. The following morning (8-12 hours after co-occupation), the vaginal opening of the female mice was examined for the presence of a mating plug. The day the mating plug was detected was recorded as day 0.5 of pseudopregnancy (E0.5). For mNSET transplantation, the optimal transplantation window for recipient mice was 2.5 days of pseudopregnancy, at which time the implantation rate was highest.
[0044] 3. Non-surgical embryo transfer
[0045] The transfer was performed using the mNSET™ non-surgical embryo transfer device (model 60010, Paratechs), which is a single-use, EtO-sterilized device. The mNSET was fixed to a P-2 pipette with a volume setting of 1.8 μL. 15 μL of M2 was added to a 60 mm culture dish cap. Using a standard embryo pipette, 3–5 cynomolgus blastocysts were transferred into the culture medium drop. The pipette was pressed down to the first stop, and the mNSET tip was immersed in the culture medium and slowly aspirated the embryos before withdrawing it. The pipette was then adjusted to 2.0 μL, creating a small air bubble at the tip to prevent embryo re-aspiration. Without anesthesia, place the recipient female mouse on top of a wire mesh cage, allowing her to grasp the mesh with her forepaws. Use your thumb and forefinger to stabilize the base of her tail and lift it upwards, while gently pressing down on the tail base with your other hand to expose the vaginal opening. Insert a small speculum into the vagina; a larger speculum may be used if necessary to clearly expose the cervix. Holding a pipette, gently pass the mNSET device through the speculum into the cervix. When the device hub contacts the speculum, press the plunger (to the first stop) to expel the embryo into the uterine cavity. While keeping the plunger in place, withdraw the device and remove the speculum. Return the mouse to its cage; postoperative resuscitation and observation are not required.
[0046] 4. Confirmation of pregnancy
[0047] Seven days after transplantation, the recipient mice were sacrificed, and the uterus was removed to observe whether implantation had occurred.
[0048] The results are as follows Figure 5 Unlike the typical implantation sinus visible to the naked eye in mouse embryos, implantation in cynomolgus monkey embryos induces diffuse edema in the recipient mouse uterus, with localized tissue protrusions, which this study identified as implantation sinuses; further tissue sections confirmed the presence of blastocyst structures within them. Figure 6 This validates the feasibility of using the model to assess the implantation potential of primate embryos.
[0049] IV. Addition of rhPRG4 protein to culture
[0050] Given that PRG4 is a secreted protein, this invention adds recombinant human PRG4 (rhPRG4) protein to the embryo culture medium at an appropriate concentration. Eight hours after fertilization, the embryos are transferred to a culture system containing the protein and cultured to the blastocyst stage. Embryos without any treatment are used as a control group.
[0051] V. Statistical analysis of implantation outcomes after early embryo in vitro culture and embryo transfer
[0052] Embryos from both the control and experimental groups were cultured under the same conditions (37 ℃, 5% CO2, 5% O2, 90% N2). The medium was changed on days 3, 5, and 7, and developmental status was recorded. Blastocyst rate (%) = (number of blastocysts on day 7 / total number of dividing embryos) × 100%. Paired t-tests were performed on the blastocyst rates of the two groups using GraphPad Prism software. Figure 7 As shown, a p > 0.05 was considered insignificant (marked as "ns" in the figure). The analysis results showed that there was no significant difference between the experimental group and the control group (p > 0.05). Therefore, it can be concluded that the blastocyst formation rate of cynomolgus monkey embryos was not significantly different between the two groups after treatment with PRG4 protein.
[0053] like Figure 8 As shown, embryos cultured to the blastocyst stage using PRG4 protein were transferred into the uterus of immunodeficient NOD-Scid mice (xenograft model). Implantation was observed on day seven post-transfer. Results showed that 4 out of 5 mice with blastocysts treated with PRG4 protein became pregnant, significantly increasing the pregnancy rate from 37.5% (3 / 8) in the control group to 80.0% (4 / 5). These results indicate that while PRG4 protein supplementation does not affect blastocyst formation rate, it can improve embryo implantation ability.
Claims
1. Application of rhPRG4 as a medium additive in improving the implantation rate of in vitro culture of mammalian embryos after embryo transfer.
2. Application of PRG4 as a target point for improving the implantation rate of in vitro culture of early mammalian embryos.
3. Use according to claim 2, characterized in that, PRG4 as a positive regulatory factor for improving the implantation rate of in vitro culture of early mammalian embryos.
